31.08.2021 PharmaSGP Holding SE  DE000A2P4LJ5

DGAP-News: PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK


DGAP-News: PharmaSGP Holding SE / Key word(s): Mergers & Acquisitions
PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK

31.08.2021 / 17:43
The issuer is solely responsible for the content of this announcement.

PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK

Gräfelfing, August 31, 2021 - PharmaSGP Holding SE announces the formal completion of the purchase agreement signed mid of June with GlaxoSmithKline Group on the acquisition of an OTC portfolio comprising the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R).

The completion of the purchase strategically strengthens PharmaSGP's operations by further expanding the category "Health Brands", enlarging the scope of indications and tapping new markets. Natalie Weigand, CEO of PharmaSGP, was very satisfied with the transaction: "The acquisition and integration of established brands with potential for value growth is a key component of our growth strategy. Baldriparan(R) has been established on the market for 67 years and is the leading OTC brand for natural valerian sleeping aids sold in pharmacies in Germany. We are thus opening up the new indication of sleep disorders. Additionally, Formigran(R), Spalt(R) and Kamol(R) strengthen our strategically important category 'pain therapy'". These four iconic brands with a long tradition in their target markets enjoy a high level of trust and loyalty with consumers, physicians and pharmacists. In 2020, the products of the brand portfolio were distributed in eight countries. Thus, the Group will also be active in Switzerland, Hungary, Poland, Czech Republic and Slovakia in future.

Michael Rudolf, CFO of PharmaSGP, considers the transaction as an achievement of a further milestone on the growth path: "With our products in the field of sleeping disorders and pain therapy, we address two of the best-selling and further growing indications in pharmacies. Thanks to our pan-European platform, we will be able to leverage potential for value enhancement. This is going to positively impact the business development in the year 2021 and beyond. We are convinced of this!"

In September, PharmaSGP will publish a consolidated revenues and earnings forecast for the financial year 2021, including the effects of Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R).


cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: [email protected]



PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with the focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio is expanded by the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R), thus also strengthening or developing the indications pain and sleep disorder.

In 2020, PharmaSGP generated revenues of EUR 63.2 million at an adjusted EBIT margin of 26.1 %.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.

31.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 21
82166 Gräfelfing
E-mail: [email protected]
Internet: https://pharmasgp.com
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich
EQS News ID: 1230068

End of News DGAP News Service

1230068  31.08.2021 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 0,00 53,06 60,59 62,57 63,25 65,34 85,82
EBITDA1,2 0,00 15,74 19,93 22,82 14,73 18,49 26,93
EBITDA-Marge3 0,00 29,66 32,89 36,47 23,29 28,30 31,38
EBIT1,4 0,00 15,33 19,55 22,42 14,25 14,92 17,68
EBIT-Marge5 0,00 28,89 32,27 35,83 22,53 22,83 20,60
Jahresüberschuss1 0,00 11,78 14,73 16,71 10,64 10,69 11,95
Netto-Marge6 0,00 22,20 24,31 26,71 16,82 16,36 13,92
Cashflow1,7 0,00 14,25 8,43 17,63 15,46 12,24 24,71
Ergebnis je Aktie8 0,00 0,98 1,23 1,39 0,89 0,89 1,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,45 0,49
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

PharmaSGP Holding
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2P4LJ 18,750 - 225,00
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,50 21,26 0,72 21,04
7,33 9,10 2,62 9,86
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
0,49 0,58 3,09 28.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.05.2023 28.09.2023 28.11.2023 27.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-12,48% -26,63% -29,51% -26,47%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu PharmaSGP Holding SE  ISIN: DE000A2P4LJ5 können Sie bei EQS abrufen

Gesundheit , A2P4LJ , PSG , XETR:PSG